Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson B, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–54.
Article
CAS
PubMed
Google Scholar
Fiskus W, Mitsiades N. B-Raf inhibition in the clinic: present and future. Annu Rev Med. 2016;67:29–43.
Article
CAS
PubMed
Google Scholar
Rahman MA, Salajegheh A, Smith RA, Lam AK. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas. Exp Mol Pathol. 2015;99:492–7.
Article
CAS
PubMed
Google Scholar
Thiel A, Ristimäki A. Toward a molecular classification of colorectal cancer: the role of BRAF. Front Oncol. 2013;3:281.
Article
PubMed
PubMed Central
Google Scholar
Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol. 2010;322:8–28.
Article
CAS
PubMed
Google Scholar
Martin-Liberal J, Larkin J. Vemurafenib for the treatment of BRAF mutant metastatic melanoma. Future Oncol. 2015;11(4):579–89.
Article
CAS
PubMed
Google Scholar
Hertzman Johansson C, Egyhazi Brage S. BRAF. Inhibitors in cancer therapy. Pharmacol Ther. 2014;142:176–82.
Article
CAS
PubMed
Google Scholar
Rahman MA, Salajegheh A, Smith RA, Lam AK. BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects. Curr Cancer Drug Targets. 2014;14:128–43.
Article
CAS
PubMed
Google Scholar
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3.
Article
CAS
PubMed
Google Scholar
Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov. 2013;3(5):520–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Landriscina M, Pannone G, Piscazzi A, Toti P, Fabiano A, Tortorella S, Occhini R, Ambrosi A, Bufo P, Cignarelli M. Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. Thyroid. 2011;21(11):1227–34.
Article
CAS
PubMed
Google Scholar
Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92(7):2840–3.
Article
CAS
PubMed
Google Scholar
Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, Fagin JA. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013;98(5):E829–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AMT, Antonetti R, Cignarelli M, Landriscina M. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2012;97(6):E898–906.
Article
CAS
PubMed
Google Scholar
Condelli V, Maddalena F, Sisinni L, Lettini G, Swann Matassa D, Piscazzi A, Palladino G, Amoroso MR, Esposito F, Landriscina M. Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma. Oncotarget. 2015;6(26):22298–309.
Article
PubMed
PubMed Central
Google Scholar
Condelli V, Piscazzi A, Sisinni L, Swann Matassa D, Maddalena F, Lettini G, Vittorio Simeon V, Palladino G, Amoroso MR, Trino S, Esposito F. Landriscina M.TRAP1 Is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. Cancer Res. 2014;74(22):6693–704.
Article
CAS
PubMed
Google Scholar
Lettini G, Sisinni L, Condelli V, Matassa DS, Simeon V, Maddalena F, Gemei M, Lopes E, Vita G, Del Vecchio L, Esposito F, Landriscina M. TRAP1 regulates stemness through Wnt/β-catenin pathway in human colorectal carcinoma. Cell Death Differ. 2016;23(11):1792–803.
Article
CAS
PubMed
Google Scholar
Maddalena F, Laudiero G, Piscazzi A, Secondo A, Scorziello A, Lombardi V, Matassa DS, Fersini A, Neri V, Esposito F, Landriscina M. Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca2+ homeostasis. Can Res. 2011;71(24):7659–69.
Article
CAS
Google Scholar
Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878–87.
Article
CAS
PubMed
Google Scholar
Kugel CH, Aplin AE. Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell Melanoma Res. 2014;27(6):1032–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hertzman Johansson C, Egyhazi Brage S. BRAF inhibitors in cancer therapy. Pharmacol Ther. 2014;142(2):176–82.
Article
CAS
PubMed
Google Scholar
Xing J, Liu R, Xing M, Trink B. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun. 2011;404(4):958–62.
Article
CAS
PubMed
Google Scholar
Liu R, Liu D, Xing M. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab. 2012;97(2):E173–82.
Article
CAS
PubMed
Google Scholar
Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: MD anderson cancer center off label experience. J Clin Endocrinol Metab. 2015;100(1):E77–81.
Article
CAS
PubMed
Google Scholar
Rahman MA, Salajegheh A, Smith RA, Lam AK. Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas. Endocrine. 2016;54(1):29–38.
Article
Google Scholar
Rahman MA, Salajegheh A, Smith RA, Lam AK. Multiple proliferation-survival signalling pathways are simultaneously active in BRAF V600E mutated thyroid carcinomas. Exp Mol Pathol. 2015;99(3):492–7.
Article
CAS
PubMed
Google Scholar
Kandil E, Tsumagari K, Ma J, Abd Elmageed ZY, Li X, Slakey D, Mondal D, Abdel-Mageed AB. Synergistic inhibition of thyroid cancer by suppressing APK/PI3K/AKT Pathways. J Surg Res. 2013;184(2):898–906.
Article
CAS
PubMed
Google Scholar
Rothenberg SM, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib-response. Clin Cancer Res. 2015;21(24):5640–1.
Article
PubMed
Google Scholar
Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA. Sustained ERK inhibition maximizes responses of BRAFV600E thyroid cancers to radioiodine. J Clin Invest. 2016;126(11):4119–24.
Article
PubMed
PubMed Central
Google Scholar
Kawalec P, Malinowska-Lipień I, Brzostek T, Kózka M. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. Expert Rev Anticancer Ther. 2016;16(12):1303–9.
Article
CAS
PubMed
Google Scholar
Yao TW, Zhang J, Prados M, Weiss WA, James CD, Nicolaides T. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Oncotarget. 2015;6(26):21993–5.
Article
PubMed
PubMed Central
Google Scholar
Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 2016;6(12):1352–65.
Article
CAS
PubMed
Google Scholar